TY - JOUR
T1 - Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations
AU - Deboever, Nathaniel
AU - Zhou, Nicolas
AU - McGrail, Daniel James
AU - Tomczak, Katarzyna
AU - Oliva, Jacqueline L.
AU - Feldman, Hope A.
AU - Parra, Edwin
AU - Zhang, Jianjun
AU - Lee, Percy P.
AU - Antonoff, Mara B.
AU - Hofstetter, Wayne L.
AU - Mehran, Reza J.
AU - Rajaram, Ravi
AU - Rice, David C.
AU - Roth, Jack A.
AU - Swisher, Stephen S.
AU - Vaporciyan, Ara A.
AU - Altan, Mehmet
AU - Weissferdt, Annikka
AU - Tsao, Anne S.
AU - Haymaker, Cara L.
AU - Sepesi, Boris
N1 - Publisher Copyright:
Copyright © 2023 Deboever, Zhou, McGrail, Tomczak, Oliva, Feldman, Parra, Zhang, Lee, Antonoff, Hofstetter, Mehran, Rajaram, Rice, Roth, Swisher, Vaporciyan, Altan, Weissferdt, Tsao, Haymaker and Sepesi.
PY - 2023
Y1 - 2023
N2 - Background: Malignant pleural mesothelioma (MPM) is associated with poor prognosis despite advances in multimodal therapeutic strategies. While patients with resectable disease may benefit from added survival with oncologic resection, patient selection for mesothelioma operations often relies on both objective and subjective evaluation metrics. We sought to evaluate factors associated with improved overall survival (OS) in patients with mesothelioma who underwent macroscopic complete resection (MCR). Methods: Patients with MPM who received neoadjuvant therapy and underwent MCR were identified in a prospectively maintained departmental database. Clinicopathologic, blood-based, and radiographic variables were collected and included in a Cox regression analysis (CRA). Response to neoadjuvant therapy was characterized by a change in tumor thickness from pretherapy to preoperative scans using the modified RECIST criteria. Results: In this study, 99 patients met the inclusion criteria. The median age of the included patients was 64.7 years, who were predominantly men, had smoking and asbestos exposure, and who received neoadjuvant therapy. The median change in tumor thickness following neoadjuvant therapy was –16.5% (interquartile range of -49.7% to +14.2%). CRA demonstrated reduced OS associated with non-epithelioid histology [hazard ratio (HR): 3.06, 95% confidence interval (CI): 1.62–5.78, p < 0.001] and a response to neoadjuvant therapy inferior to the median (HR: 2.70, CI: 1.55–4.72, p < 0.001). Patients who responded poorly (below median) to neoadjuvant therapy had lower median survival (15.8 months compared to 38.2 months, p < 0.001). Conclusion: Poor response to neoadjuvant therapy in patients with MPM is associated with poor outcomes even following maximum surgical cytoreduction and should warrant a patient-centered discussion regarding goals of care and may therefore help guide further therapeutic decisions.
AB - Background: Malignant pleural mesothelioma (MPM) is associated with poor prognosis despite advances in multimodal therapeutic strategies. While patients with resectable disease may benefit from added survival with oncologic resection, patient selection for mesothelioma operations often relies on both objective and subjective evaluation metrics. We sought to evaluate factors associated with improved overall survival (OS) in patients with mesothelioma who underwent macroscopic complete resection (MCR). Methods: Patients with MPM who received neoadjuvant therapy and underwent MCR were identified in a prospectively maintained departmental database. Clinicopathologic, blood-based, and radiographic variables were collected and included in a Cox regression analysis (CRA). Response to neoadjuvant therapy was characterized by a change in tumor thickness from pretherapy to preoperative scans using the modified RECIST criteria. Results: In this study, 99 patients met the inclusion criteria. The median age of the included patients was 64.7 years, who were predominantly men, had smoking and asbestos exposure, and who received neoadjuvant therapy. The median change in tumor thickness following neoadjuvant therapy was –16.5% (interquartile range of -49.7% to +14.2%). CRA demonstrated reduced OS associated with non-epithelioid histology [hazard ratio (HR): 3.06, 95% confidence interval (CI): 1.62–5.78, p < 0.001] and a response to neoadjuvant therapy inferior to the median (HR: 2.70, CI: 1.55–4.72, p < 0.001). Patients who responded poorly (below median) to neoadjuvant therapy had lower median survival (15.8 months compared to 38.2 months, p < 0.001). Conclusion: Poor response to neoadjuvant therapy in patients with MPM is associated with poor outcomes even following maximum surgical cytoreduction and should warrant a patient-centered discussion regarding goals of care and may therefore help guide further therapeutic decisions.
KW - cytoreductive resection
KW - malignant pleural mesothelioma
KW - neoadjuvant therapy
KW - patient-centered care
KW - radiographic response
UR - http://www.scopus.com/inward/record.url?scp=85168794920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168794920&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1216999
DO - 10.3389/fonc.2023.1216999
M3 - Article
C2 - 37637041
AN - SCOPUS:85168794920
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1216999
ER -